Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seman JJ, Knight RD, Mellars K, Heffernan M, Reitsma DJ: Pamidronate reduces skeletal morbidity in women with advance breast cancer and lytic bone lesions: A randomised, placebo-controlled trial. J Clin Oncol. 1999, 17: 846-854.
CAS
PubMed
Google Scholar
Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med. 1996, 335: 1785-1791. 10.1056/NEJM199612123352401.
Article
CAS
PubMed
Google Scholar
Coleman RE: Management of bone metastases. The Oncologist. 2000, 5: 463-470.
Article
CAS
PubMed
Google Scholar
Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, Yunus F, Bell R, Body J, Quebe-Fehling E, Seaman J: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomised, controlled clinical trials. J Clin Oncol. 2001, 19: 558-567.
CAS
PubMed
Google Scholar
Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, Dreicer R, Kuross SA, Lipton A, Seaman JJ: Zoledronic acid reduces skeletal related events in patients with osteolytic metastases: a double-blind, randomised dose-response study. Cancer. 2001, 91: 1191-1200. 10.1002/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0.
Article
CAS
PubMed
Google Scholar
Coleman R, Apffelstaedt J, Major P, Mackey J, Howell A, Theriault R, Gordon D, Ambros Y: Zometa is equivalent to pamidronate in the prevention of skeletal related events secondary to metastatic breast cancer treated with hormonal therapy [abstract]. Eur J Cancer. 2001, 37(6): S152-10.1016/S0959-8049(01)81045-5.
Article
Google Scholar
Body JJ, Lichinitser MR, Diehl IE, Schlosser K, Pfarr E, Cavalli V, Dornoff V, Gorbuova VA, McCloskey E, Weiss J, Kanis JA: Double-blind placebo controlled trial of ibandronate in breast cancer metastatic to bone [abstract]. Proc ASCO. 1999, 18: 575a-
Google Scholar
Coleman RE, Purohit OP, Black C, Vinholes JJ, Schlosser K, Huss H, Quinn KJ, Kanis J: Double-blind, randomised, placebo-controlled study of oral ibandronate in patients with metastatic bone disease. Ann Oncol. 1999, 10: 311-316. 10.1023/A:1008386501738.
Article
CAS
PubMed
Google Scholar
Body JJ, Bartl R, Burckhardt P, Delmas PD, Diel IJ, Fleish H, Kanis JA, Kyle RA, Mundy GR, Paterson AH, Rubens RD: Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol. 1998, 16: 3890-3899.
CAS
PubMed
Google Scholar
Jagdev SP, Purohit OP, Heatley S, Herling C, Coleman RE: Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol. 2001
Google Scholar
Berenson JR, Lipton A, Rosen LS: Phase I clinical study of a new bisphosphonate, zoledronate (CGP-42446), in patients with osteolytic bone metastases [abstract]. Blood. 1998, 88(suppl 1): 586a-
Google Scholar
Vinholes JJ, Purohit OP, Abbey ME, Eastell R, Coleman RE: Relationships between biochemical and symptomatic response in a double-blind trial of pamidronate for metastatic bone disease. Ann Oncol. 1997, 8: 1243-1250. 10.1023/A:1008238422151.
Article
CAS
PubMed
Google Scholar
Diel IJ, Marschner N, Kindler M, Lange O, Untch M, Hurtz HJ, Bre-itbach GP, Richter B: Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases [abstract]. Proc ASCO. 1999, 18: 128-
Google Scholar
Conte PF, Latreille J, Mauriac L, Calabresi F, Santos R, Campos D, Bonneterre J, Francini G, Ford JM: Delay in progression of bone metastases treated with intravenous pamidronate: Results from a multicentre randomised controlled trial. J Clin Oncol. 1996, 14: 2552-2559.
CAS
PubMed
Google Scholar
Hultborn R, Ryden S, Gunderson S, Holmberg E, Wallgren U-B: Efficacy of pamidronate on skeletal complications from breast cancer metastases. A randomised prospective double blind placebo controlled trial. Acta Oncol. 1996, 35(suppl 5): 73-74.
Article
Google Scholar
Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seamann JJ: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast cancer and osteolytic bone metastases: long-term results of two randomised, placebo-controlled trials. Cancer. 2000, 88: 1082-1090. 10.1002/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.3.CO;2-Q.
Article
CAS
PubMed
Google Scholar
Lipton A, Demers L, Curley E, Chinchilli V, Gaydos L, Hortobagyi G, Theriault R, Clemens D, Costa L, Seaman J, Knight R: Markers of bone resorption in patients treated with pamidronate. Eur J Cancer. 1998, 34: 2021-2026. 10.1016/S0959-8049(98)00277-9.
Article
CAS
PubMed
Google Scholar
Fontana A, Delmas PD: Osteoporosis in cancer patients. In Cancer and the Skeleton. Edited by Rubens RD, Mundy GR. London: Martin Dunitz Ltd;. 2000, 263-270.
Google Scholar
Powles TJ, Paterson AHG, Nevantaus A, Legault S, Pajunen M, Tidy VA, Rosenquist K, Smith IE, Ottestad L, Ashley S, Walsh G, McCloskey E, Kanis JA: Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer [abstract]. Proc ASCO. 1998, 17: 468-
Google Scholar
Diel I, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998, 339: 357-363. 10.1056/NEJM199808063390601.
Article
CAS
PubMed
Google Scholar
Saarto T, Blomqvist C, Virkkunen P, Eloma A: Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol. 2001, 19: 10-17.
CAS
PubMed
Google Scholar
Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DI, Mak TW, Boyle WJ, Penninger JM: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999, 397: 315-323. 10.1038/16852.
Article
CAS
PubMed
Google Scholar
Honore P, Luger NM, Sabino AC, Schwei MJ, Rogers SD, Mach DB, O'Keefe PF, Ramnaraine ML, Clohisy DR, Mantyh PW: Osteoprotogerin blocks bone cancer-induced skeletal destruction. Skeletal pain and pain-related neurochemical re-organisation of the spinal cord. Nat Med. 2000, 6: 521-528. 10.1038/74999.
Article
CAS
PubMed
Google Scholar
van Holten-Verzantvoort AT, Bijvoet OLM, Cleton FJ, Hermans J, Kroon HM, Harinck HI, Vermey P, Elte JW, Neijt JP, Beex LV: Reduced morbidity from skeletal metastases in breast cancer patients during long term bisphosphonate (APD) treatment. Lancet. 1987, ii: 983-985. 10.1016/S0140-6736(87)92555-4.
Article
Google Scholar
Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S: Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 1993, 11: 59-65.
CAS
PubMed
Google Scholar